![logo](/logos/NXTC.webp)
NextCure, Inc.
NASDAQ:NXTC
1.42 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | NextCure, Inc. |
Symbool | NXTC |
Munteenheid | USD |
Prijs | 1.42 |
Beurswaarde | 39,725,636 |
Dividendpercentage | 0% |
52-weken bereik | 0.98 - 2.57 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael S. Richman MSBA |
Website | https://www.nextcure.com |
An error occurred while fetching data.
Over NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)